Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...
Raymond James and Cantor both released bullish notes on uniQure (NASDAQ:QURE) Tuesday in the wake of news that the company ...
The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...
Verition Fund Management LLC lowered its position in uniQure (NASDAQ:QURE – Free Report) by 77.9% during the third quarter, ...
RBC Capital raised the firm’s price target on uniQure (QURE) to $20 from $14 and keeps an Outperform rating on the shares. uniQure announced ...
Qure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130.